Abstract
This study evaluates the effectiveness of chemical facet joint and sacroiliac joint block as a treatment for chronic low back pain associated with facet syndrome and sacroiliitis. Low back pain is a common cause of disability, and these conditions are often underdiagnosed. The research was conducted at the Regional Hospital of Tlalnepantla ISSEMYM between August 2017 and July 2018 through an experimental, comparative, prospective, and longitudinal study, with clinically and radiologically diagnosed patients. A combination of betamethasone, lidocaine, and ropivacaine was used, administered through fluoroscopy-guided injection in the lumbar and sacroiliac regions. Pain and disability were assessed using the Visual Analog Scale (VAS) and the Oswestry Disability Index, both before and after the procedure, with follow-up at 2, 4, 8, 12, and 24 weeks. Results showed significant improvement in pain and functionality through ANOVA statistical analysis. The VAS indicated a progressive decrease in pain, while the Oswestry scale showed a significant reduction in disability. Both instruments demonstrated statistically significant results (P < 0.05), confirming the procedure’s effectiveness. In conclusion, the chemical facet and sacroiliac joint block is a safe, effective, and clinically useful method for managing chronic low back pain when conservative treatments have failed. Its use improves patients’ quality of life and reduces the need for more invasive surgical interventions.